Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
By J. Reginster, E. Seeman, M. D. Vernejoul, S. Adami, J. Compston, C. Phenekos, J. Devogelaer, M. Curiel, A. Sawicki, S. Goemaere and 3 more. Journal of Clinical Endocrinology and Metabolism, 2005
1,102 citations recorded by the source corpus.
Subfields: Molecular Biology, Oral Surgery, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/fbd472f6f9c408d68d97a6817199a256960d1296
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Surmeneva
- R. Surmenev
- F. Saltel
- A. Ivanova
- E. Bonnelye
- A. Chabadel
- P. Jurdic
Citations in the corpus
- Significance of calcium phosphate coatings for the enhancement of new bone osteogenesis--a review. (2014, background): “Strontium is a trace element that stimulates bone cell growth and bone resorption and suppresses osteoporosis via opposite effects on bone resorption and formation [346-349].”
- Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. (2008, background): “Strontium ranelate is a newly developed drug that has been shown to be effective in reducing the risk of vertebral and hip fractures in postmenopausal women with osteoporosis [25,31].”